COMP <GO>
NIVF vs CCEL // EV/EBITDA & P/E VALUATION
NewGenIvf Group Limited (Class A) (NASDAQ) VS. Cryo-Cell International Inc. (NYSE) • 15-METRIC TALLY: NIVF 0
— CCEL 4
■ METRIC PARITY
LAST: $1.14 (-5.00%) • MKT CAP: $11.3M
valuation
—
LAST: $5.19 (+1.17%) • MKT CAP: $41.8M
valuation
61.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NIVF VS. CCEL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NIVF | CCEL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.80% | 18.20% | -51.00 | CCEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 61.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 12.55% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 68.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -13.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 7.73% | -7.73 | CCEL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.63 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 22.5 | 64.3 | -41.77 | CCEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.3M | $41.8M | -$30.5M | CCEL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NIVF REV | CCEL REV | NIVF GROSS % | CCEL GROSS % | NIVF FCF | CCEL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.7M | $0 | 20.2% | — | -$11.1M | $5.2M |
| FY 2024 | $5.4M | $0 | 33.6% | — | -$8.3M | $3.6M |
| FY 2023 | $5.1M | $0 | — | — | -$1.8M | $8.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NIVF // BETA —
CCEL // BETA —